The different effects of phenothiazines on cardiac action potential duration

Basic and Clinical Pharmacology and Toxicology

Volumn 96, Issue 2, 2005, Pages 143-

  Shin, Won Ho ^a   Kim, Eun Joo ^a  

^a Korea Research Institute of Chemical Technology   (South Korea)

Author keywords

[No Author keywords available]

Indexed keywords

CHLORPROMAZINE; NEUROLEPTIC AGENT; PHENOTHIAZINE DERIVATIVE; POTASSIUM CHANNEL HERG; THIORIDAZINE; TRIFLUOPERAZINE;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CONTROLLED STUDY; DOSE RESPONSE; DRUG EFFECT; DRUG FATALITY; HEART MUSCLE POTENTIAL; HEART VENTRICLE TACHYCARDIA; MEMBRANE STEADY POTENTIAL; NONHUMAN; PRIORITY JOURNAL; QT PROLONGATION; SUDDEN DEATH;

ANIMALIA;

EID: 14644396112     PISSN: 17427835     EISSN: None     Source Type: Journal    
DOI: 10.1111/j.1742-7843.2005.pto960209.x     Document Type: Article

References (21)

1. Bigger, Jr. J. T. & F. M. Weld: Drugs and sudden cardiac death. Ann. NY Acad. Sci. 1982, 382, 229-327.
2. Buckley, N. A. & P. Sandres: Cardiovascular adverse effects of anti-psychotic drugs. Drug safety 2000, 23, 215-228.
3. Chiang, C., H. Luk, T. Wang & P. Y. Ding: Effects of sildenafil on cardiac repolarization. Cardiovasc. Res. 2002, 55, 290-299.
4. De ponti, F., E. Poluzzi & N. Montanaro: QT-interval prolongation by non-cardiac drugs: lessons to be learned from recent experience. Eur. J. Clin. Pharmacol. 2000, 56, 1-18.
5. Drolet, B., F. Vincent, J. Rail, M. Chahine, D. Deschenes, S. Nadeau, M. Khalifa, B. A. Hamelin & J. Turgeon: Thioridazine lengthens repolarization of cardiac ventricular myocytes by blocking the delayed rectifier potassium current. J. Pharmacol. Exp. Therap. 1999, 288, 1261-1268.
6. Fayer, S. A.: Torsades de pointes ventricular tachyarrhythmia associated with haloperidol (letter). J. Clin. Psychopharmacol 1986, 6, 375-376.
7. Flanagan, R. J.: Guidelines for the interpretation of analytical toxicology results and unit of measurement conversion factors. Ann. Clin. Biochem. 1998, 35, 261-267.
8. Glassman, A. H.: Cardiovascular effects of tricyclic antidepressants. Annu. Rev. Med. 1984, 35, 503-511.
9. Glassman, A. H. & J. T. Bigger: Antipsychotic drugs: Prolonged QTc interval, Torsade de Pointes, and sudden death. Amer. J. Psychiatry 2001, 158, 1774-1782.
10. 2+ channels in rat pheochromocytoma cells. Biochem. Pharmacol. 1999, 58, 1017-1024.
11. Liberatore, M. A. & D. S. Robinson: Torsades de pointes: A mechanism for sudden death associated with neuroleptic drug therapy? J. Clin. Psychopharmacol. 1984, 4, 143-146.
12. Martin, R. L., J. S. McDermott, H. J. Salmen, J. Palmatier, B. F. Cox & G. A. Gintant: The utility of hERG and repolarization assays in evaluating delayed cardiac repolarization: Influence of multi-channel block. J. Cardiovac. Pharmacol. 2004, 43, 369-379.
13. Mehtonen, O. P., K. Aranko, L. Malkonen & H. Vapaatalo: A survey of sudden death associated with the use of phenothiazine or antidepressant drugs: 49 cases in Finland. Acta. Psychiatr. Scand., 1991, 84, 58-64.
14. Pacher, P., J. Magyar, P. Szigligeti, T. Bányász, C. Pankucsi, Z. Korom, Z. Ungvári, V. Kecskeméti & P. P. Nánási: Electrophysiological effects of fluoxetine in mammalian cardiac tissues. Naunyn-Schmiedeberg's Arch. Pharmacol. 2000, 361, 67-73.
15. Redfern, W. S., L. Carlsson, A. S. Davis, W. G. Lynch, I. MacKenzie, S. Palethorpe, P. K. S. Siegl, I. Strang, A. T. Sullivan, R. Wallis, A. J. Camm & T. G. Hammond: Relationships between preclinical cardiac electrophysiology, clinical QT interval prolongation and torsade de pointes for a broad range of drugs: evidence for a provisional safety margin in drug development. Cardiovasc. Res. 2003, 58, 32-45.
16. ca, in single frog cardiac cells by quinidine, flecainide, eyhmozin, and ethacizin. Amer. J. Physiol. 1989, 256, C549-C559.
17. Studenik, C., R. Lemmens-Gruber & P. Heistracher: Proarrhythmic effects if antidepressants and neuroleptic drugs on isolated, spontaneously beating guinea-pig Purkinje fibers. Eur. J. Pharm. Sci. 1998, 7, 113-118.
18. Thomas, D., K. Wu, S. Kathöfer, H. A. Katus, W. Schoels, J. Kiehn & C A. Karle: The antipsychotic drug chlorpromazine inhibits HERG potassium channel. Brit. J. Pharmacol. 2003, 139, 567-574.
19. Tie, H., B. D. Walker, S. M. Valenzuela, S. N. Breit & T. J. Campbell: Dose-response curves for blockade of HERG tail currents by thioridazine, amitriptyline, and chlorpromazine. Lancet 2001, 355, 1825.
20. Warner, J. P., T. R. Barnes & J. A. Henry: Electrocardiographic changes in patients receiving neuroleptoc medication. Acta Psychiatr. Scand. 1996, 93, 311-313.
21. Welch, R. & P. Chue: Antipsychotic agents and QT changes. J. Psychiat. Neurosci. 2000, 25, 154-160.